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Abstract
Protein-protein interactions represent difficult but increasingly important targets for the design of therapeutic compounds
able to interfere with biological processes. Recently, fragment-based strategies have been proposed as attractive
approaches for the elaboration of protein-protein surface inhibitors from fragment-like molecules. One major challenge in
targeting protein-protein interactions is related to the structural adaptation of the protein surface upon molecular
recognition. Methods capable of identifying subtle conformational changes of proteins upon fragment binding are
therefore required at the early steps of the drug design process. In this report we present a fast NMR method able to probe
subtle conformational changes upon fragment binding. The approach relies on the comparison of experimental fragment-
induced Chemical Shift Perturbation (CSP) of amine protons to CSP simulated for a set of docked fragment poses,
considering the ring-current effect from fragment binding. We illustrate the method by the retrospective analysis of the
complex between the anti-apoptotic Bcl-xL protein and the fragment 49-fluoro-[1,19-biphenyl]-4-carboxylic acid that was
previously shown to bind one of the Bcl-xL hot spots. The CSP-based approach shows that the protein undergoes a subtle
conformational rearrangement upon interaction, for residues located in helices a2, a3 and the very beginning of a5. Our
observations are corroborated by residual dipolar coupling measurements performed on the free and fragment-bound
forms of the Bcl-xL protein. These NMR-based results are in total agreement with previous molecular dynamic calculations
that evidenced a high flexibility of Bcl-xL around the binding site. Here we show that CSP of protein amine protons are
useful and reliable structural probes. Therefore, we propose to use CSP simulation to assess protein conformational changes
upon ligand binding in the fragment-based drug design approach.
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Introduction
Protein-Protein Interactions (PPI) play a major role in a large
diversity of processes in cells [1]. PPI represent consequently
highly attractive targets for the elaboration of chemical probes in
chemical biology. PPI are also important therapeutic targets for
the design of inhibitors capable of preventing the formation of
protein-protein complexes and interfering with biological path-
ways. However, tackling PPI remains a particularly challenging
task in drug design due to the properties of PPI surfaces, by
comparison with more typical binding sites of proteins. Protein-
protein interfaces happen to be rather flat and large and are
therefore less prone to interact with ligands than smaller and
deeper pockets found in binding sites of proteins such as enzymes
[2–6]. A novel approach in drug design called Fragment-Based
Drug Design (FBDD) seems to be a very promising methodology
and could help developing PPI inhibitors [2,7,8]. FBDD consists of
screening fragment-like molecules against protein targets, using
biophysical methods such as Surface Plasmon Resonance, Nuclear
Magnetic Resonance and X-ray crystallography [9,10]. Fragments
are small, simple and very low molecular weight compounds
(MWv300 Da) that usually bind proteins with low affinity
(mMvKDvmM). Fragments nevertheless bind proteins through
high-quality interactions and display high ligand efficiencies
[11,12]. Potent compounds with improved activities (KI&nM)
are derived from fragment hits by growing, merging or linking
methods [9,13]. PPI inhibitors resulting from fragment-based
approaches have been reported for the Bcl-2 family [14–18], for
interleukins [19], and for the ZipA/FtsZ interaction [20]. Very
recently, FBDD methods have been successfully applied to target
the Ras/SOS complex [21,22] and the BRCA2/RAD51 complex
[3].
Protein conformational changes upon ligand interaction make
rational drug design even more complicated and challenging.
Regarding fragment-like molecules, it is not fully accepted in the
scientific community that such ligands can induce protein
rearrangement, mostly because they bind proteins with very weak
affinities [2]. However, as recently reviewed, resolution of 3D
structures of fragment-protein complexes revealed that fragments
could induce conformational change, even if they bind proteins
with low affinity [23]. All these subtle protein conformational
changes upon fragment binding were evidenced by X-ray
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crystallography, through the comparison of the free protein and
the complex structures [2,23–26]. X-Ray is clearly the method of
choice for resolving structures, but sometimes it can be difficult to
get crystals for protein-fragment complexes. Such structures can
also be determined by NMR, using NOESY experiments, but the
analysis is much longer and requires the full protein spectrum
assignment. Here, we propose to use a very sensitive NMR
parameter, the chemical shift, to compare the free and fragment-
bound conformations of the protein. The analysis focuses on
protein amine groups that can be rapidly assigned. Upon ligand
recognition, proton chemical shifts of the protein are perturbed by
the change in chemical environment due both to the presence of
the ligand and to possible structural changes. The method
described in this report relies on the fact that the large majority
of fragments contain aromatic moieties. Aromatic rings are
responsible for the so-called ring current shift effect [27], which
constitutes the major contribution of the ligand-induced proton
Chemical Shift Perturbations (CSP) in protein NMR spectra. The
ring current shift caused by aromatic rings can be simulated by
semi-classical equations, using the Haigh-Maillon model [27–30].
Thus, disagreement between experimental fragment-induced CSP
and simulated fragment-induced CSP should highlight structural
rearrangements of the protein upon interaction. Using 2D 1H-15N
protein spectra, protein residues located in regions that undergo
conformational change upon fragment binding will be identified.
To illustrate the method, we analyse the interaction of the Bcl-xL
protein with a fragment that lead to the discovery of inhibitors
ABT737 and ABT263, the most advanced fragment-based
application of a PPI inhibitor [16,31,32].
Bcl-xL, as a member of the Bcl-2 family of proteins, is involved
in the regulation of apoptosis. In normal cells, the anti-apoptotic
proteins including Bcl-xL promote cell survival, while the pro-
apoptotic members such as Bak and Bad promote cell death [33–
35]. 3D structures of Bcl-xL bound to peptides from pro-apoptotic
proteins showed that the protein undergoes rearrangement upon
interaction, involving in particular the shift of the protein helix a3
[36–38]. Upon binding to PPI inhibitors, Bcl-xL structure is also
modified, but the conformational change observed on helix a3
depends on the inhibitor size [16,39,40]. Regarding fragment-like
ligands, Bcl-xL conformational change upon interaction has not
been clearly investigated. Fragment-based NMR screening of 104
compounds performed against Bcl-xL identified fragment 1 (49-
fluoro-[1,19-biphenyl]-4-carboxylic acid) as the best hit with a
dissociation constant of 300 mM [15]. The structure of the protein-
fragment complex has been calculated by docking the fragment
into the protein structure using intermolecular protein-ligand
NOEs obtained from 13C, 15N filtered NOESY experiments (PDB
code 1YSG). During the calculation, the protein structure was kept
rigid except for binding site residues [15], so the true structure of
the protein-fragment complex has not been resolved. More
recently, the group of Constantine applied the NOE matching
approach to analyse the Bcl-xL/fragment 1 complex [41,42]. The
authors used four different Bcl-xL structures, in the presence of
Bak (1BXL), an NMR apo structure (1LXL), a X-Ray apo
structure (1MAZ), and the fragment-bound structure 1YSG. The
results suggested that the true fragment-bound structure might be
more similar to the peptide-bound Bcl-xL structure (1BXL) than
the 1YSG structure or the apo structures [42]. Here, to investigate
Bcl-xL conformational change upon fragment binding, we
compare fragment-induced experimental CSP with simulated
CSP resulting from the ring current effect of fragment positions
docked in the protein binding site. The analysis reveals that the
protein undergoes structural rearrangements involving residues of
helices a2, a3 and a5. To confirm the results and go further into
the characterisation of the fragment-induced conformational
change, we performed Residual Dipolar Coupling (RDC) exper-
iments, which are sensitive to the orientation of the backbone
amine groups [43,44]. RDC have been previously used to explore
protein conformational changes upon protein-protein interactions
[45,46] and protein-ligand interactions [47,48]. RDCs were
measured on the free and fragment-bound forms of Bcl-xL. The
comparison of experimental RDCs and back-calculated RDCs on
available protein structures confirms subtle Bcl-xL conformational
changes upon fragment interaction. Thus, we propose to use
proton CSPs as structural probes for investigating protein
conformational changes upon fragment binding, and discuss the
advantages and limits of the method.
Results
Experimental Bcl-xL Chemical Shift Perturbations upon
binding to fragment 1
To investigate Bcl-xL conformational changes upon fragment
binding, 2D NMR spectra were recorded for the protein in the
absence and the presence of increasing concentrations of the
compound 1 (Figure 1). Significant and linear shifts are observed
for some of the 1H-15N cross-peaks, while a large number of
residue peaks display no perturbations, indicating a specific
binding onto the binding site. Combined CSP including proton
and nitrogen resonances (CSP(HzN)) are mapped into the 3D
structure of the free Bcl-xL protein in Figure 2 (see equation 3).
The binding of fragment 1 induces large chemical shift
perturbations for residues located in helices a2 (Gly94, Phe97,
Glu98, Leu99, Tyr101 and Arg102), a3 (Asp107, Thr109 and
Ser110) and a5 (Asn136, Trp137, Glu138, Arg139, Ile140 and
Ala142). CSP are specifically observed for residues located into the
groove of Bcl-xL that corresponds to the binding site of the
apoptotic proteins [36–38]. More precisely, the fragment binding
site corresponds to the Bcl-xL preferred hot spot of fragments, as
previously demonstrated by fragment-based screening [15] and a
NMR-based analysis of fragments resulting from deconstruction of
Bcl-xL inhibitors [49]. Experimental proton CSP (CSPH ) values
are displayed in red lines along the protein sequence in Figure 3.
Generation of Bcl-xL/1 complex structures for the
calculation of fragment-induced CSPH values
To compare experimental CSPH values with fragment-induced
simulated CSPH values, 3D structures of Bcl-xL-fragment
complexes are required. In the method we use here, the structure
of the free protein should be available. To allow a large
conformational sampling for the CSP simulation, 200 positions
of fragment 1 were generated into the free structure of Bcl-xL
binding site (1R2D) using AutoDock software [50]. As illustrated
in Figure 4, five clusters are obtained with similar binding energies
ranging from 24.3 kcal.mol21 to 25.7 kcal.mol21. Clearly, the
binding mode of fragment 1 on Bcl-xL surface is driven by the
interaction of the fragment carboxylate with the guanidinium of
Bcl-xL arginine residues. Seventy-two out of the 200 positions
interact with Arg132 (cluster 1, red), 37 with Arg139 (cluster 2,
blue), 34 (cluster 3, orange) and 43 (cluster 4, purple) with Arg100,
while 24 positions interact with Arg103 (cluster 5, green). In fact,
the docked positions in cluster 2 are very similar to the previously
NOE-guided docked position of the fragment in the Bcl-xL/1
complex, as illustrated in Figure S1. In the published model
(1YSG), fragment 1 interacts with Bcl-xL through an interaction
with Arg139, which correlates with the observation that the
modification of the carboxyl group position resulted in a dramatic
decrease of affinity [15]. The hydrophobic biphenyl moiety is in
Fragment-Induced Chemical Shift Perturbations
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contact with residues Phe97, Tyr101, Ala104, Phe105, Leu130,
Gly138, Arg139 and Ala142 (Figure S1).
Comparison of Experimental and Simulated CSPH of Bcl-
xL upon binding to fragment 1
CSP simulation for the 200 docked structures is shown in blue
points in Figure 3. For each amide proton of Bcl-xL, the CSPH
value is simulated for the 200 ligand positions and compared to the
experimental CSPH observed for the same Bcl-xL amide proton.
In addition, in supplementary material, results are displayed for
the five clusters in distinct graphs (Figure S2). As illustrated on
Figure 3, significant differences between experimental CSPH
values (red) and CSPH values simulated for the 200 fragment
positions (blue points) are observed.
In the approach we report here, we compare experimental
CSPH values with simulated CSPH values. Cases where experi-
mental CSPH are larger than simulated CSPH have to be
distinguished from cases where the reverse is observed. Simulated
CSPH values can become very large when the amine proton is
very close (in van der Waals interaction) to an aromatic proton of
the ligand (Figure S3). This is the case for example in cluster 1 for
residues Leu130 and Phe131 or in cluster 4 for residue Arg139
(Figure S2). Such results are obtained when the docking program
places the ligand very close to the protein. Additionally, when
saturation is not reached, maximal experimental CSPH values can
be limited by the dissociation constant of the complex, while
simulated CSPH values are calculated for a saturated binding site.
Therefore, we focus here on residues for which experimental
CSPH values are larger than simulated CSPH values, as it is
unexpected if no protein rearrangement occurs.
As shown in Figure 3, five amide protons located in helix a2
(Phe97 and Glu98), helix a3 (Thr109, Ser110) and helix a5
(Ala142) exhibit experimental CSPH values much larger than the
maximal simulated value (Dexperimental CSPH - simulated
CSPH Dw0.2 ppm). In addition, three residues of helix a2 (Ala93,
Leu99 and Tyr101) as well as two residues of helix a3 (Asp107 and
Ile114) exhibit differences larger than 0.06 ppm. When looking
separately at each cluster, similar conclusion is drawn. For cluster
1, cluster 2 and cluster 4, experimental CSPH values larger than
simulated CSPH values (Dexperimental CSPH - simulated
CSPH Dw0.2 ppm) are observed for residues 97, 98, 101, 102,
109, 110 and 142. For cluster 3, residues exhibiting large
experimental CSPH values are 97, 98, 101, 109, 110 and 142,
and for cluster 5, residues are 97, 98, 109, 110 and 142. A Pscore
factor was calculated for all the 200 docked positions to estimate
the disagreement between experimental and simulated CSPH
values (see equation 5). The Pscore ranges from 0.0069 to 0.0165,
and the average Pscore values for the five clusters are similar
(0.0087 for cluster 1, 0.0083 for cluster 2, 0.0093 for cluster 3,
Figure 1. 15N-HSQC spectra of the Bcl-xL protein in the
presence of fragment 1. (A) Structure of fragment 1. (B)
Superimposition of the 15N-HSQC protein spectra in the free state
(blue) and in the presence of increasing ligand concentration (200 mM
in cyan, 300 mM in green, 500 mM in yellow, 700 mM in orange, 1 mM in
red, 2 mM in pink and 4 mM in purple). (C) Section of the 15N-HSQC
spectrum. Numeration was done according to the PDB code 1R2D.
doi:10.1371/journal.pone.0064400.g001
Figure 2. Binding site of fragment 1 mapped onto the protein
Bcl-xL surface. (A) The combined shift perturbations CSP(HzN)
induced by fragment 1 mapped onto the protein surface. Residues
that exhib i t large perturbat ions are disp layed in red
(CSP(HzN)§0:4ppm) and orange (0:4wCSP(HzN)§0:15 ppm). (B)
Ribbon structure of Bcl-xL in the free state (PDB code 1R2D) with the
seven helices coloured sequentially.
doi:10.1371/journal.pone.0064400.g002
Figure 3. Experimental versus simulated CSPH values. Simulated
CSPH (blue points) are calculated for the 200 structures displayed in
Figure 4. Experimental CSPH values (red lines) are superimposed to the
simulated CSPH values. Residues 25 to 84 that are absent in the
structure 1R2D are removed from the plot.
doi:10.1371/journal.pone.0064400.g003
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0.0082 for cluster 4, and 0.0092 for cluster 5), indicating that none
of the clusters exhibit a good agreement between experimental and
simulated CSPH values.
The residues for which experimental CSPH values cannot be
explained by the ring current shift of the ligand are mapped on the
protein backbone in Figure 5A. The CSPH analysis we report here
clearly highlights structural rearrangement of Bcl-xL upon
fragment binding, likely including backbone movement and side
chain reorientation for residues located in helices a2 and a3. In
addition, the experimental CSPH value of residue Ala142 from
helix a5 does not correlate with any simulated value. Ala142 is
located in the Bcl-xL hot spot and very near from the residue
Phe97. The latter might slightly move upon interacting with
fragment 1, inducing chemical shift perturbation for Ala142.
Residual dipolar coupling measurements for the free and
fragment-bound forms of Bcl-xL
To confirm the conclusion resulting from the CSPH analysis
and validate the use of CSPH as reliable probes for assessing
protein conformational changes upon binding to fragment-like
molecules, we also analysed Residual Dipolar Coupling (RDCs)
for the free and fragment-bound forms of Bcl-xL. RDCs are a
powerful source of long-range orientational information and are
very sensitive to structural variations from known protein
structures [43–45,47]. The RDC of a 15N-11H pair value depends
on the orientation of the N-H vectors with respect to the alignment
tensor of the molecule and thus the direction of every 15N-1H
bond vector along the protein backbone would provide powerful
assessment of the validity of any proposed structure. When 3D
structures of proteins are available, RDCs can be back-calculated
from the structure and compared with the measured RDCs
[45,47]. Thus, it is possible to compare any form of a protein with
a published structure. The correlation coefficient r between the
experimental RDCs recorded in the absence of fragment and the
RDCs back-calculated from the free 1R2D Bcl-xL structure is 0.97
(Figure 6B). This indicates that 1R2D is a good model for the
RDC analysis and that the solution structure in our experimental
conditions is very similar to the published apo X-Ray structure
1R2D. The correlation slightly decreases to 0.92 when the back-
calculated RDCs are compared to RDCs measured in the
presence of the fragment. The outliers in the correlation plot
correspond to residues of helix a3 (Ala104, Gln111 and His113)
and helix a5 (Arg139 and Ala142) (Figure 6). Regarding helix a5,
all residues but Arg139 and Ala142 exhibit a good correlation
between experimental RDCs and back-calculated RDCs, suggest-
ing that helix a5 does not move. Only the beginning of the helix,
which is in direct contact with fragment 1, is perturbed, in
agreement with the CSPH data. Regarding helix a3, three of the
residues have a good correlation coefficient, three other residues
could not be analysed due to spectral overlapping, and three
residues located at both extremities of the helix (Ala104, Gln111
and His113) exhibit significant differences. The RDC measure-
ments therefore confirm that a subtle conformational change upon
binding to fragment 1 takes place in the binding region. The NH
bonds of the residues with a bad correlation have a different
orientation in the bound structure. The RDCs results are therefore
in very good agreement with the CSPH analysis (Figure 5B).
To go further into the analysis of the RDCs, we have focused
the analysis on the a2 and a3 helices. Experimental RDCs are now
compared to RDCs back-calculated using eight different Bcl-xL
structures including apo (PDB codes 1R2D and 1LXL), ligand-
bound (PDB codes 1YSG, 2O2M and 2YXJ) and peptide-bound
(PDB codes 1G5J, 2PON and 1BXL) structures. The structures
are described in Table 1 and compared in Figure 7. The
correlation coefficient r between experimental and back-calculated
RDCs ranges from 0.43 for 1G5J to 0.95 for 2O2M, and is 0.64
for 1R2D (Figure 8). The correlation is clearly better with ligand-
bound structures (average r=0.85) than with the free structures
(average r=0.63) or the peptide-bound structures (average
r=0.45). RDC measurements confirm that fragment 1 induces
Bcl-xL adaptation upon interaction for residues located in helix a3
and the top of helix a5, and indicate that the rearrangement is
more similar to the one observed in the presence of ligands such as
in 2O2M than the one observed in the presence of peptide ligands.
Figure 4. Docked positions of fragment 1 on the protein Bcl-xL
binding surface. (A) Superposition of 200 structures of fragment 1
docked into the Bcl-xL binding site. Five clusters are observed (72 poses
in red, 37 in blue, 24 in green, 24 in orange and 43 in magenta). (B)
Energy binding (in kcal/mol) histogram for the 5 clusters.
doi:10.1371/journal.pone.0064400.g004
Figure 5. NMR evidences of Bcl-xL conformational change
upon fragment binding. (A) CSPH analysis. Significant differences
between experimental and simulated CSPH mapped onto the protein
surface (DCSPH -CSPH D§0.06 ppm). (B) RDC analysis. Residues with
DRDCexp-RDCcalc Dw6.5 Hz are displayed.
doi:10.1371/journal.pone.0064400.g005
Fragment-Induced Chemical Shift Perturbations
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Discussion
Recently, Surade and Blundell reviewed factors that make drug
discovery difficult [2]. Among those factors, protein structural
adaptation for efficient protein-ligand recognition was considered
as a major problem in rational drug design. The authors recall that
fragment-like molecules can induce conformation change but this
is kinetically and thermodynamically less likely than for drug-like
molecules. Protein conformational change can hamper the FBDD
approach, since binding sites may be induced by the ligand, or
protein conformers may be stabilised from an ensemble upon
ligand recognition [2]. To date, few reports deal with fragment-
induced protein conformational changes. Using X-ray crystallog-
raphy, Babaoglu and Shoichet identified fragments that bound
very weakly to the AmpC b-lactamase by inducing a novel binding
site into the enzyme. The fact that crystallisation conditions were
similar to those of the apo structure lead to the suggestion that the
observed modification was not an artifact but a specific
accommodation of these fragments [25]. Fragment-based screen-
ing of the HIV PR also identified fragment binding associated with
conformational change in the protein [24]. Recently, a review by
Murray and collaborators shows that out of 25 targets, 12
exhibited movement greater than 5 A [23]. For example, in
HSP90, some fragments induced the so-called collapsed helix
formation around residue Gly108. For the well-known case of the
BACE protein, fragments can induce significant conformational
change in the Glycine-rich loop. Additional protein movement
involving Asp168 swinging to form a hydrogen bond with the
fragment OH group has also been observed [51]. All these reports
were obtained from the resolution of the free and fragment-bound
structures of the protein by X-Ray crystallography. Here, we
demonstrate using NMR based on CSP and RDC measurements
that Bcl-xL undergoes subtle local protein rearrangement upon
fragment binding, involving residues of helices a2 and a3, and the
very beginning of helix a5. This is an additional report showing
that fragments can induce protein rearrangements upon interac-
tion.
The RDC measurements show that Bcl-xL conformational
change upon fragment binding is not as large as those induced by
peptide ligands such as Bak, Bad or Beclin-1 [18,51,56] (Figure 8).
This is not surprising since helix a3 shift upon peptide binding was
shown to depend on the so-called position P1 of the peptide
ligands [39]. This position is not occupied by fragment 1 which
binds the protein hot spot [15,49]. In addition, ligands such as
those in structures 2O2M and 2YXJ have different impact on Bcl-
xL structures, showing that Bcl-xL clearly adapts its conformation
to the ligand [16,40,52,53] (see Table 1 and Figure 7). Here we
observe that a small ligand with 16 heavy atoms and a low affinity
(KD =300 mM) induces Bcl-xL movement upon interaction, and
this rearrangement is roughly similar to the one observed in a
ligand-bound structure (2O2M), at least for the backbone
conformation. In general, this raises the question of the intrinsic
flexibility of proteins that accommodate various conformations
depending on the ligands. For Bcl-xL, the backbone flexibility was
recently characterised by MD simulations [52,53]. Starting from
the structures bound to the Bad peptide, the structures did not
reach the conformational space shown on the apo structures.
Order parameters were compared for apo, holo without the
peptide and holo with peptide structures. The region of helices a2
and a3 is flexible and the backbone flexibility is significantly
reduced in the holo structure with peptide; for holo without
peptide, higher degrees of flexibility in the loop a2-a3 and a3-a4
are observed when compared to the peptide-bound forms [53].
The higher degree of flexibility around helix a3 revealed in MD
simulation correlates with the change of the length and
conformation of helix a3 when binding to the peptide ligands,
and correlates with the fragment-induced conformational changes
revealed by our CSP and RDC analysis.
In the absence of protein conformational change, the main
contributions to the ligand-induced chemical shift perturbations
for proton CSP (CSPH ) are the ring-current effect of the ligand
aromatic rings and the hydrogen bonds between the protein and
Figure 6. Experimental versus back-calculated RDC on the free protein structure. (A) Comparison of the experimental RDC measured for
the free protein and the calculated RDC using the free protein structure 1R2D. (B) Comparison of the experimental RDC measured in the presence of
fragment 1 and the back-calculated RDC using the free protein structure 1R2D. Residues exhibiting DRDCexp-RDCcalcDw6.5 Hz are labelled.
doi:10.1371/journal.pone.0064400.g006
Figure 7. PDB structures of Bcl-xL in free and complexed states.
Helix a3 that moves upon ligand binding is coloured differently for the
ligand-bound structures (1YSG, red; 2O2M, blue and 2YXJ, purple), for
the peptide-bound structures (1G5J, cyan; 1BXL, yellow and 2PON,
green), and for the free structure (1R2D, orange).
doi:10.1371/journal.pone.0064400.g007
Fragment-Induced Chemical Shift Perturbations
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the ligand [30,54,55]. Nitrogen chemical shifts are more difficult
to interpret and have not been used yet for analysing protein-
ligand complexes. Fragment-like molecules represent simple
organic compounds with few chemical functions and a very low
molecular weight (v300 Da) that typically contain at least one
aromatic ring. The ring current effect will therefore be largely
predominant in the fragment-induced proton CSPH . Hydrogen
bond effects can be large, but this typically affects few protein
residues, while ring-current effects are spread around the aromatic
ring up, as illustrated in Figure S3. In addition, simulation of
protein-ligand hydrogen bonds is still problematic [55–58].
Quantitative analysis of CSPH for protein-ligand interactions has
been reported for the first time by McCoy and Wyss in 2000 [30].
Ligand-induced CSPH simulation has been used the last decade by
three different groups for assessing ligand binding modes [55,59–
61]. The CSPH simulation consists of calculating the ring current
effect on proton chemical shifts using the Haigh-Mallion model
(equation 4). In the published reports, experimental CSPH are
compared to CSPH simulated from docked ligand positions with
semi-classical methods. The ligand binding mode corresponds to
the ligand position exhibiting the best agreement between
experimental and simulated CSPH values. Published cases are
the complexes formed between calmodulin and a naphthalene
derivative using a Trp probe [30], HCV NS3 protease and a series
of weak-affinity ligands [59], the protein antitumor antibiotic NSC
and a synthetic chromophore analogue [60], barnase and
deoxyoligonucleotides [61] and three kinase-ligand complexes
[55]. In these examples where the ligand binding mode is deduced
from the quantitative analysis of CSPH , it is required that the
protein does not undergo any conformational changes upon ligand
binding. If the protein experiences a rearrangement upon
interaction, experimental CSPH will contain direct contributions
from the ligand (ring current shifts) and indirect contributions due
to protein conformational rearrangements such as backbone
movements and side chain reorientations. For example, when
rearrangement involves reorientation of aromatic residues, ring
current effects of Phe, Tyr and Trp side chains will contribute to
the CSPH observed. For Bcl-xL, reorientation of aromatic sides
chains of residues Phe97, Tyr101 and Phe105 have been observed
(Figure S4). The aromatic ring movements could contribute to the
large CSPH observed for residues in their vicinity. Finally, it is
important to notice that RDC measurements on the free protein
shows that 1R2D is a good starting structural model; therefore
CSP disagreements do not result from divergences between the X-
Ray Bcl-xl structure used for the docking and the structure in
solution. In addition, RDC measurements complement CSP data
as they show that the backbone of Bcl-xL is also modified in the
helix a3 upon ligand interaction.
Here we do not solve the structure of the fragment-protein
complex but we propose to use a fast NMR method to assess if an
induced fit process is observed upon fragment binding. An
assigned 2D NMR spectrum is necessary, which is easily feasible
for proteins below 50 kDa. In addition, an apo 3D structure of the
protein is required. When only a protein structure in a presence of
a ligand is available, it is also possible to take the holo structure as
the 3D model; disagreements will show that the protein
coordinates have changed and that the holo and apo structure
differ. For example, CSPH values simulated with the ligand-bound
Figure 8. Experimental versus back-calculated RDC for helices
a2 and a3. Comparison of the experimental RDC measured for the
protein-fragment 1 complex and the back-calculated RDC on 8 different
PDB structures: (A) 1R2D (B) 1LXL (C) 1YSG (D) 2O2M (E) 2YXJ (F) 1G5J
(G) 2PON (H) 1BXL (See Table 1 for more details).
doi:10.1371/journal.pone.0064400.g008
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2O2M Bcl-xL structure clearly highlight similar disagreements
between experimental and simulated CSPH values, with an
average Pscore value of 0.008 (Figure S5). Using the apo Bcl-xL
structure or the holo 2O2M Bcl-xL structure, experimental CSPH
values for residues 97, 98, 101, 109, 110 and Ala142 are never
explained by any ligand positions, showing that these residues are
located in a region that moves upon ligand recognition.
Disagreement between experimental and simulated CSPs larger
than 0.2 ppm are observed for these residues. Previously published
examples showed that in the absence of conformational change,
we should not observe discrepancies between experimental and
simulated CSPH [30,60,61].
Conclusion
Protein-protein interfaces represent therapeutic targets for the
future drugs. These interfaces are typically large and flexible, and
as a consequence still remain a real challenge for drug discovery.
Methods able to detect protein structural rearrangements upon
interactions should therefore be useful in this context, to identify
proteins subject to conformational change, to locate theses
changes, and to compare structural modifications with MD
calculations. The results we report here demonstrate that CSPH
analysis could be routinely used for this purpose.
Materials and Methods
Proteins production and purification
The protein Bcl-xL was expressed as a 6His-tagged protein in
Escherichia coli strain BL21(DE3 gold) using pQE-30 expression
vector. E. Coli were grown at 37oC in M9 minimal medium
supplemented with thiamine and containing 15NH4Cl as the sole
nitrogen source to produce uniformly 15N-labelled protein. The
protein expression was induced with isopropyl b-D-1-thiogalacto-
pyranoside (0.5 mM) for 2 h. Cells were then lysed in 20 mM
imidazole, 20 mM sodium phosphate, 500 mM NaCl supple-
mented by lysozyme and DNase (pH=7.4) by sonification and
clarified by centrifugation. The 6His-tagged protein contained in
the supernatant was purified onto a His GraviTrap column (GE
Healthcare) by Ni2+-affinity chromatography. The protein was
eluted with 500 mM imidazole, 20 mM sodium phosphate buffer
and 500 mM NaCl. The protein buffer was then exchanged by
dilution/concentration cycles, against 25 mM sodium phosphate,
(pH=7.0) containing 3 mM DTT (Dithiothreitol).
CSP measurements
NMR samples contained 200 mM uniformly 15N-labelled Bcl-
xL and ligand concentrations from 0 to 4 mM (saturation). The
concentration of DMSO-d6 did not exceed 3% in the NMR tube.
2D 15N-HSQC spectra were acquired at 28oC with a Varian
Inova 600 MHz NMR spectrometer, equipped with a standard
5 mm triple-resonance inverse probe with z-axis field gradient,
using 64 t1 increments. Control 1D spectra preceded all
experiments to assess the purity and stability of the fragment. All
NMR spectra were processed with the Varian Vnmrj and the
NMRPipe softwares and analysed using NMRView and Sparky
[62–64].
The proton and nitrogen chemical shift perturbations (CSPH
and CSPN , respectively) induced by the fragment were defined as
the difference between the chemical shift of the protein in the
bound and the free states (see eq.1 and eq.2).
CSPH~d
1Hbound{d
1Hfree ð1ÞT
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CSPN~d
15Nbound{d
15Nfree ð2Þ
The combined perturbation CSP(HzN) was calculated using the
proton (CSPH ) and the nitrogen (CSPN ) chemical shift perturba-
tions [65]:
CSP(HzN)~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(CSPH )
2z
(CSPN )
2
25
2
s
: ð3Þ
Docking calculation
The generation of 200 ligand poses located in the binding site
was performed using AutoDock4 with the AutoDockTools4
graphical interface [50]. Grid maps were generated with
0.375 A spacing into the protein binding site. The docking
calculations were performed using Genetic Algorithm (GA) for
ligand conformational searching. The 3D structure used was the
apo X-ray structure 1R2D. The protein was kept rigid during the
docking procedure.
CSP simulation
CSPH were calculated by means of the Haigh-Maillon semi-
classical model [27] (eq.4) widely used for CSPH calculation on
amide proton and in other popular programs (SHIFTX [28],
SHIFTS [29], Shifty [66], CH3Shift [67] and SPARTA [68]):
CSPH~fB
X
ij
Sij(
1
r3i
z
1
r3j
): ð4Þ
Here, f is the ring-specific intensity factor (1.00 for benzene type
ring), B is the target nucleus factor (B~7:06 10{6 for amide nuclei
[28]). Other values for f and B can be found in a recent work [69].
ri and rj are the distances from the ring atoms i and j to the proton
HN of the protein. Sij is the area of the triangle formed by atom i
and j and the HN proton projected onto the plane of the aromatic
ring. The sums are over the bonds in the ring.
We wrote a Fortran program to calculate the CSPH induced by
a fragment position on each protein amide proton. The program
needs ligand PDB file (provide by docking experiments) and
associated protein PDB file to load nucleus coordinates (available
formats: .pdb and .pdbqt). To evaluate the agreement of the
simulation with experimental CSPH a factor Pscore was introduced
in the program and calculate for each pose (j):
Pscore(j)~
1
N
X
i
(CSPexp(i){CSPsim(i))
2: ð5Þ
The number of protein residues was considered by N (N=196
for Bcl-xL). Low Pscore indicates that the docking solution is in
good agreement with the experimental CSP. Nevertheless, the
ligand-protein complex likely exists as energetically close-states,
that are not necessarily discriminated by the CSP and the Pscore
values, especially since simulated CSP only contain ring-current
shift contributions.
RDC
HN RDCs were measured in 25 mM sodium phosphate,
50 mM NaCl, 3 mM DTT at 28oC with IPAP-type experiment
[70] using 20 mg/mL of Pf1 LP11-92 phage. RDC experiments
were performed for the protein Bcl-xL alone (350 mM) and in the
presence of the fragment (2 mM). In the presence of anisotropic
medium, the 2H signal splitting was 20+5 Hz for the free and
fragment-linked of Bcl-xL. This ensure that similar degree of
alignment is used for both. 256 increments t1 were recorded in the
indirect dimension 15N and RDC values were obtained from the
differences in the 15N-1H coupling observed in the isotropic and
anisotropic case. RDCs ranged from 233 Hz to 29 Hz and from
233 Hz to 23 Hz for the protein in the free state and in the
presence of the fragment 1 respectively. Residues showing
overlapped signals were removed from the analysis that was
performed with the in-house program ALTENS [71]. The RDCs
were back-calculated as previously published [71], using data
collected in both presence and absence of ligand according to the
method of Singular Value Decomposition (SVD) [72]. To account
for the goodness of the fit, correlation factors r (Pearson factor) and
quality factors Q were calculated [73].
Supporting Information
Figure S1 Bcl-xL/fragment 1 complex. (A) Docked Bcl-xL-
fragment complex that best mimics the complex structure
available in the PDB (included in cluster 2). (B) Bcl-xL-fragment
1 structure determined by Petros and coworkers (PDB code
1YSG). For both, hydrophobic residues are shown in yellow and
residues labelled in bold are involved in hydrogen bond or
electrostatic interaction (Ligplot+ analysis [74]).
(TIF)
Figure S2 Experimental versus simulated CSPH values.
Experimental CSPH values (red lines) are superimposed to the
simulated CSPH values calculated using the PDB file 1R2D (blue
points). Comparison between experimental and calculated results
are shown for (A) cluster 1, (B) cluster 2, (C) cluster 3, (D) cluster 4
and, (E) cluster 5. Residues 25 to 84 are removed from the plot.
(TIF)
Figure S3 Iso-shielding curves of the ring current effect
induced by a benzene ring on chemical shift amide
proton. The chemical shift perturbations values calculated
according to the Haigh-Mallion theory are labelled on each curve
and expressed in ppm. Iso-shielding curves (A) in the benzene ring
plane (B) in the plane perpendicular to the benzene ring plane.
(TIF)
Figure S4 Aromatic rings located in helices a2 and a3 of
Bcl-xL. Each structure is coloured by PDB code to compare the
position of (A) Phe97, (B) Tyr101, and (C) Phe105.
(TIF)
Figure S5 Experimental CSPH values versus simulated
CSPH values calculated with the structure 2O2M.
Simulated CSPH (blue points) are calculated for the 200 structures
using the PDB file 2O2M. Experimental CSPH values (red lines)
are superimposed to the simulated CSPH values. Residues 25 to 84
are removed from the plot.
(TIF)
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